ArticleResearch in pharmaceutical sciences2025
Clinical relevance of circulating biomarkers in breast cancer metastasis detection: "insights from liquid biopsy technology".
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acyl-coenzyme A synthetase long-chain 4 (ACSL4) expression and human epidermal growth factor receptor 2 (HER2) status with metastasis and survival in breast cancer: a five-year follow-up.Research in pharmaceutical sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Breast cancer is a major global concern, especially because of high mortality linked to advanced stages. Metastasis may occur early, but current diagnostics struggle to detect small metastatic cells. Non-invasive liquid biopsies, such as circulating miRNA, ctDNA, and cfDNA, present a promising solution for screening and monitoring breast cancer. This study aimed to examine the clinical relevance of circulating levels of cfDNA, miR-182, CYFRA21-1, and CEA in metastatic and non-metastatic breast cancer patients and their association with clinical stage and distant metastasis. Experimental approach: Ten mL blood samples were collected from 17 metastatic and 29 non-metastatic breast cancer patients pre-surgery. cfDNA was measured fluorometrically, miRNA-182 Findings/Results: Results demonstrated significantly higher levels of cfDNA, miR-182, CYFRA21-1, and CEA in women with metastatic breast cancer compared to those with non-metastatic breast cancer. These markers were linked to advanced clinical stages and increased tumor size. Elevated levels of cfDNA, miR-182, and CYFRA21-1 were indicative of a higher risk for lymphatic metastasis, while cfDNA and CYFRA21-1 were associated with distant metastasis. ROC curve analyses revealed strong efficacy for cfDNA (AUC 0.94), miR-182 (AUC 0.91), CYFRA21-1 (AUC 0.88), and CEA (AUC 0.87) in detecting metastatic breast cancer. Conclusion and implications: Combined analysis of these biomarkers will enhance the predictive accuracy of metastatic breast cancer and clarify the relationship between biomarker profiles and the characteristics of metastatic versus nonmetastatic patients using liquid biopsy technology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.